Danaher Corporation

DHR

 $\mathcal{O}$ 

Healthcare

Medical - Diagnostics & Research

May 2025

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions, The Life Sciences segment provides mass spectrometers: flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation. consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and guality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia. THEDIVIDENDPRINCE.COM Price 52 week low 52 week high Total shares outstanding Market cap Exchange market 199.05 171.0 281.7 716 Millions shares 142 Billions NYSE Thedividendprince rating\* Revenue (In millions \$) Profit Margin (In %) 6.33/10 40,000 25.00% **Key Metrics** 20.00% Blue Chips Yes 30.000 Brand ranking\*\* No Ranking 15.00% Revenue (CAGR) 10 years 1.48% × 20.000 10.00% Net income (CAGR) 10 years 1.15% 0.76% EPS (CAGR) 10 years 10.000 5 00% 37.87 Price earnings ratio Net Profit Margin TTM 15.81% 0.00% 1 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 TTM 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 TTM Dividend payout ratio 20.85% 1 Dividend yield 0.57% Free Cash Flows (In millions \$) Nb of outstanding shares (In millions) 10.86% Return on equity (10y average) Return on Tangible assets (10y average) 24.07% 800 8,000 Return on Invested Capital TTM 5 5 3% 600 6,000 0.46 Debt to equity (10y average) Debt to assets (10y average) 0.25 400 4.000 Price to book ratio TTM 3 56 Fair Value (Morningstar) 270 200 2.000 Wide Economic Moat (Morningstar) A3 Long term debt rating (Moody's) P-2 Short term debt rating (Moody's) 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 TTM 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 TTM 12 50% Dividend Cut Risk Score 8.52 ESG Risk Rating (Morningstar) **Dividend History** Return on \$1000 invested Financial Strength Score (Piotroski Score) 8 📕 dividends 🛛 💻 Payout ratio - DHR returns - S&P 500 (SPX) Last Earning Call AI Sentiment Analysis neutral 25% 1.25 \$6,000 Stock beats the ref. index for the last 10 years 1 \$5.000 1.00 20% steady revenue? Steady net income ? \$4,000 0.75 15% Steady profit margin positive ? \$3.000 10% 0.50 Steady FCF ? \$2.000 steady dividends and increasing ? 0.25 5% Nb of shares decreasing ? \$1,000 0.00 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Thedividendprince rating is explained here \*\*Brand ranking source

Disclaimer :Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this document should be seen as a recommendation to follow any investment strategy. Errors may occur.

